Regeneron Pharmaceuticals, Inc. (REGN) Posts Q2 Loss of 69c/Share

July 28, 2011 7:16 AM EDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q2 EPS of ($0.69), $0.28 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $107.8 million versus the consensus estimate of $121.51 million.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings